TITLE:
Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis

CONDITION:
Ulcerative Colitis

INTERVENTION:
Asacol 800 mg (mesalamine)

SUMMARY:

      This study is a prospective clinical study to evaluate the safety and efficacy of two
      different doses of Asacol for the treatment of moderately active ulcerative colitis. In
      addition, a new tablet formulation will be evaluated at one of the two doses.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 75 Years
Criteria:

        Inclusion Criteria:

          -  male or female between 18 and 75 years of age;

          -  have a confirmed diagnosis of ulcerative colitis with the extent varying from
             proctitis to pancolitis;

          -  currently demonstrating moderately active disease

        Exclusion Criteria:

        Patients will be excluded from admission to the study if they have/are:

          -  a history of allergy or hypersensitivity to salicylates or aminosalicylates;

          -  a history of extensive small bowel resection (>1/2 the length of the small intestine)
             causing short bowel syndrome;

          -  current renal or hepatic disease;

          -  participated in any drug or device clinical study within 30 days of entry;

          -  currently enrolled in any other clinical study;

          -  received any oral, intravenous, intramuscular, or rectally administered
             corticosteroids within 1 month prior to the Baseline Visit;

          -  received any other topical rectal therapy during the week prior to the Screening
             Visit;

          -  received immunomodulatory therapy including, but not limited to, 6-mercaptopurine,
             azathioprine, cyclosporine, or methotrexate within 3 months prior to the Baseline
             Visit;

          -  received a dose of mesalamine-containing compound by any route from which more than
             1.6 g/day of mesalamine was available within 1 week prior to the Screening Visit
             (NOTE: 4 g/day of sulfasalazine and 4.5 g/day of balsalazide are equivalent to 1.6
             g/day of mesalamine);

          -  received antibiotics, other than topical antibiotics, within 1 week prior to the
             Screening Visit;

          -  received aspirin (except for cardioprotective reasons up to a maximum dose of 325
             mg/day) or NSAIDs within 1 week prior to the Baseline Visit;

          -  if female, positive pregnancy test, or lactating.
      
